Q
Quant'AbondanceL'abondance, quantifiée.

Actualités

Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.

26,000 signal articles · 188 in last 24h · 124,932 total before filter · latest 1h ago
188last 24h
1172last 7d
190● bullish (7d)
119● bearish (7d)
205publishers
AllMacro216Earnings397M&A99Regulatory17Product9Analyst9
✕ clear all filterssentiment: neutralSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Cathie Wood has strong words about Cloudflare's earnings call
TheStreet15d agoneutral
Cathie Wood has strong words about Cloudflare's earnings call

Cathie Wood, the founder of investment firm Ark Invest, has flagged what she sees as a blind spot in how Wall Street is covering Cloudflare, a major internet infrastructure company. Writing on X on August 9, Wood said she found it striking that Cloudflare's latest earnings call included no ...

Can Johnson Controls (JCI) Turn Wasted Heat Into $18B?
Insider Monkey15d agoneutral
Can Johnson Controls (JCI) Turn Wasted Heat Into $18B?

Johnson Controls International (NYSE:JCI) just found a way to sell power that the data center industry was throwing away. On July 28, the company launched its Absorption Chiller Reference Design Guide, a blueprint that converts waste heat from on-site generators into cooling capacity, freeing up electricity that would otherwise go to running chillers. In a […]

AbCellera (ABCL) Rockets 44% as Hot Flash Treatment Brightens Growth Outlook
Insider Monkey15d agoneutral
AbCellera (ABCL) Rockets 44% as Hot Flash Treatment Brightens Growth Outlook

AbCellera Biologics Inc. (NASDAQ:ABCL) rallied for a third consecutive day on Monday to hit a new three-year high, after its drug candidate for hot flashes in menopausal women achieved strong clinical trial results, sparking long-term rosy growth prospects. In intra-day trading, the stock surged to a record high of $10.01 before trimming gains to end […]

Eli Lilly vs. Novo Nordisk: Has GLP-1 Manufacturing Become the New Competitive Moat?
Insider Monkey15d agoneutral
Eli Lilly vs. Novo Nordisk: Has GLP-1 Manufacturing Become the New Competitive Moat?

The obesity-drug market has largely been viewed as a race between clinical innovation and commercial execution. Investors have spent the past three years comparing prescription growth, market share, and pipeline candidates as Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) compete for dominance in one of healthcare’s fastest-growing markets. Yet another competitive advantage for investors to […]